FactSheet

Pal l Co r po r ati o n
2200 Northern Blvd.
East Hills, New York 11548-1289

www.pall.com/investor

Quick Facts Our Business

Pall Corporation solves complex contamination,
Fiscal 2008 Sales: separations, purification and detection problems
$2.6 Billion for diverse customers around the world. These
solutions enable customers to produce high quality
World Headquarters: innovative products, remove pathogens from blood
2200 Northern Blvd. fractions, water and food, purify biotech drugs,
East Hills, New York 11548-1289 minimize waste, meet regulations and develop
breakthrough technologies. Our process and
Chairman and CEO: product enabling technologies help make good
Eric Krasnoff
products better, safer and even possible.

President:
Pall is much more than a filter company. We are
Donald Stevens
fluid management specialists leveraging our
CFO and Treasurer: unmatched capabilities to make customers more
Lisa McDermott successful. Our large library of proprietary core
materials is at the heart of these capabilities. We
Date & State of Incorporation: can modify them to separate, remove or selectively
July 31, 1946, New York capture the most elusive contaminants, proteins or
target molecules.
Listed Security:
PLL Common Stock (NYSE) All of the process fluids that course through
industry are candidates for multiple stages of
Fiscal Year End: filtration, separations and purification. Filtration
July 31 products that are selected without a holistic view
of the process are like dominoes. A slip anywhere
Organization: in the process topples everything in its path.
Two integrated businesses:
Life Sciences and Industrial Pall’s Total Fluid Management philosophy was
born of this classic cause and effect principle.
Investor Relations Contact:
Our ability to design integrated systems that link
Patricia Iannucci
all of the incoming, process and waste streams in
Vice President, Investor Relations and
a plant, then manufacture, install and service
Corporate Communications
them, is unique in our industry. We can do this for
1.866.898.7255 phone
any customer, anywhere in the world. Systems
516.484.3649 fax
piannucci@pall.com matched to the customer's process enable them
to consistently meet productivity, quality and
regulatory requirements at the lowest total cost of
ownership. By meeting critical needs, our
Pall’s Total Fluid Management SM customers reward us with business that repeats
strategy enables customers to and grows year after year.

consistently meet productivity,

quality and regulatory
requirements.

Pall Fact Sheet 10/22/08 Page 1

Pall Technologies Are Essential Medical
• Emerging Pathogens – SARS, Mad Cow, Legionella
To Industry
• Increased Emphasis on Infection Control In Hospitals
As consumers we rarely stop to consider how the
• Leukocyte Reduction is Standard of Care
products we use are made. Whether they are • New Standards Require Bacterial Detection Systems
computers or cell phones, a favorite beer or wine, • IV Drugs Ship with Filters
tap water, medicine, electricity, gasoline, or the
paint on our cars, we simply expect high quality, Industrial
reliability and reasonable prices. For the most General Industrial
part, we get them. Pall's highly sophisticated • Environmentally-friendly Processes
technologies are among the reasons why. These • Environmentally-friendly Products

100
20

40

60

80
0
technologies are invisible to consumers, but • Manufacturing Efficiency and Economics
essential to industry. • Drinking Water Regulations
• Consumer Demand for Safe Water
2008Market
Industry Sales by Market
Drivers
(amounts in millions)
The demand for filtration, separations and Microelectronics

100
20

40

60

80
purification is pervasive, continuous and growing.
0
• Solar Cells
Following are some of the latest trends fueling • Pervasive Computing
Pall's
2008growth.
Sales by Geography • Nanotechnology
(amounts in millions) • Miniaturization
Life Sciences • Benign Manufacturing
BioPharmaceuticals
• Manufacturers Race to Get Drugs to Market Aerospace & Transportation
• Explosive Growth of New Drug Targets • Long-term Military and Commercial Programs
• More Biotech Drugs in Production • Operational Efficiency and Economics
• Increasing Demand for Pharmaceuticals • Defense and Homeland Security
• New Manufacturing Processes • Passenger and Crew Safety
• Plant Consolidation, Globalization, • Contamination Sensitive Products and Processes
Standardization

Total Fiscal Year 2008 Europe Asia Western Hemisphere

Sales: $2,571.6 (in millions)

2008 Sales by Geography

(amounts in millions) $1,107.0 $654.0 $810.6
43% 25% 32%
Aerospace & Transportation

Energy, Water & Microelectronics

Process Technologies Medical BioPharmaceuticals
2008 Sales by Market
(amounts in millions) $981.3 $306.6 $308.5 $491.8 $483.4
38% 12% 12% 19% 19%

Forward-Looking Statements
The matters discussed in this publication contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-
looking statements are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ
materially. Statements about future performance, earnings projections, earnings guidance, management’s expectations about its future cash needs and
effective tax rate, and other future events or developments are forward-looking statements. Forward-looking statements are those that use terms such as
“anticipate”, “should”, “believe”, “estimate”, “expect”, “intend”, “plan”, “predict”, “potential” or similar expressions about matters that are not historical
facts. Such risks and uncertainties include those discussed in our Annual Report on Form 10-K and other reports the Company files with the Securities and
Exchange Commission. The Company makes these statements as of the date of this disclosure and expressly disclaims any obligation to update them.

© Copyright 2008, Pall Corporation. Pall, , are trademarks of Pall Corporation. ® Indicates a Pall trademark
registered in the USA. is a service mark of Pall Corporation. Pall Fact Sheet 10/22/08 Page 2